The need for cells to proliferate over the life span of an organism may place individuals at risk in the numbers game that underlies cancer. Adult stem cell lineages may have evolved to lower this risk by minimizing the chance of cells escaping the mechanisms that restrict their expansion. There is emerging evidence that some blood cell cancers and solid tumors may contain a cancer cell hierarchy reminiscent of the normal tissue in which the malignancies first arose, with a cancer stem cell producing progeny with limited replication potential (Al-Hajj et al., 2003; Lapidot et al., 1994; Singh et al., 2004) . For example, in tumors of the breast and brain, a minority population of cancer stem cells have the ability to self-renew, whereas the majority of cancer cells have limited or no ability to proliferate. This suggests that cancer stem cells may drive the growth and spread of the tumor. The presence of a stem cell population in a tumor has implications for the diagnosis and treatment of cancer, as it is these cancer stem cells that must be targeted to achieve a cure. Failure to eliminate these self-renewing cells sets the stage for the regrowth of a tumor following cessation of chemotherapy. The ability to prospectively identify cancer stem cells will allow the investigation of key molecules and pathways that could be targeted to eliminate these malignant cells.
Key steps in the progression to cancer may involve failure of normal developmental mechanisms evolved by long-lived multicellular organisms to meet the needs for renewing short-lived cell types such as those of the skin, gut, and blood. Cancers often arise in tissues such as skin, gut, and blood where constant proliferation is required to ensure a continued supply of newly differentiated cells. Replacement of the mature cells in these tissues is accomplished by a highly orchestrated process in which a relatively small population of self-renewing adult stem cells gives rise to proliferating progenitor cells (sometimes called transit-amplifying cells) that undergo limited rounds of mitotic division and then terminally differentiate, losing their ability to proliferate further (see Figure 1A ). In this hierarchical system, only the stem cells are long-lived. Indeed, although progenitor cells have some ability to replicate, their life span as proliferating cells is short, often measured in days or weeks.
Key Properties of Tissue Stem Cells
The remarkable longevity of tissue stem cells relies on their unique ability to undergo self-renewing mitotic divisions in which one or both progeny retain the stem cell identity and the capacity to replicate almost indefinitely. The daughters of stem cell divisions also have the option to follow a differentiation pathway.
The balance between self-renewal and differentiation must be strictly regulated to maintain the stem cell pool and to generate the required supply of fully differentiated cells needed for tissues to carry out their many tasks.
Stem cells in adult tissues must produce large numbers of differentiated progeny. These transitamplifying progenitor cells may undergo a limited series of mitotic cycles, sometimes referred to as transit-amplifying cell divisions, before entering a postmitotic fully differentiated state (see Figure 1A) . In this way, the activity of a relatively small number of stem cells can be amplified to produce large numbers of differentiated progeny. For example, in the male germline or the bone marrow (both of which contain well-studied stem cell populations), a relatively small number of germline or hematopoietic stem cells produce billions of sperm or mature blood cells over the life of the individual.
Did Stem Cells Evolve as a Protection against Cancer?
The evolution of single-cell organisms into multicellular animals with their specialized cell types and complex organ systems necessitated development of strict controls to keep cellular proliferation in check. If any cells in the tissue community shake loose from these constraints on proliferation, then the resulting tumor can kill the individ-ual organism. Long-lived multicellular organisms have evolved many fail-safe mechanisms to protect them against developing cancer. As a result, progression to cancer requires that a number of mutations accumulate in the same cell lineage in order to collectively circumvent these protective mechanisms. For example, progression to cancer may involve loss of normal growth controls leading to the formation of polyps, or the inactivation of the fail-safe mechanisms that compel abnormal cells to die or that prevent cells from migrating into surrounding tissues (Fearon and Vogelstein, 1990) . However, even the requirement for a single cell to accumulate several mutations before it becomes cancerous may not be sufficient to prevent longlived organisms from dying of cancer at a relatively young age. Avoiding cancer is essentially a numbers game. For example, trillions of cells are formed in the human body over (D) Genetic or epigenetic alterations in cancer stem cells enable them to become niche-independent such that they undergo cell-autonomous self-renewal generating tumors containing self-renewing stem cells and their nontumorigenic progeny, which make up the bulk of the tumor. It is possible that progression from niche dependence to independence is common during the progression of a neoplasm to a more aggressive tumor. (E) Mutations may arise that imbue transitamplifying progenitor cells with the stem cell property of self-renewal. Further genetic events in this pool of abnormally self-renewing cells culminates in a malignancy. In this example of self-renewal, the cancer stem cell is derived not from a normal stem cell but from one of its partially differentiated progeny. a normal life span, and if all of the cells in the body retain the ability to divide, there would be a reasonable chance that at least one cell would accumulate sufficient mutations to become cancerous while the organism is still young. Thus, organisms have developed a strategy to limit the number of long-lived cells with self-renewal capacity. Restricted long-term renewal of short-lived cell types may reduce the chance that a single cell with proliferative capacity will accumulate the mutations required for malignant transformation.
The counting mechanisms that normally regulate and limit the number of rounds of successive transit-amplifying cell divisions may also provide an important safeguard against cancer. Although both stem cells and transit-amplifying cells divide and produce the same endproducts-a spectrum of differentiating progeny-they differ in their ability to proliferate and maintain an undifferentiated state for an extended period of time. A single hematopoietic stem cell (HSC) can regenerate the blood system of a mouse. By contrast, a transit-amplifying progenitor cell, although descended from an HSC, cannot self-renew, and so, when transplanted into a lethally irradiated host, can only contribute to the blood system for a brief period of time (Morrison and Weissman, 1994) . With each cell division, the progeny of a hematopoietic transitamplifying cell become progressively more differentiated, with measurably reduced capacity to proliferate (see Figure 1A ). This programmed decline in replication potential may help to guarantee that progenitor cells cease proliferation and terminally differentiate before they have a chance to accumulate the multiple mutations that are required for tumor formation (see Figure 1A) .
The Crucial Role of the Stem Cell Niche
Normal stem cells share many properties with cancer stem cells, most notably the trait of self-renewal. To maintain tissue homeostasis, the number of daughter cells that retain stem cell identity must be strictly controlled such that differentiated cells can be generated in response to, for example, wounding while the stem cell pool is simultaneously replenished but not expanded. By blocking expansion of the stem cell pool, stem cells are prevented from forming tumors.
The HSC is the best understood mammalian stem cell. Mouse genetics has shown that the regulation of HSC number is under the control of multiple genes (Morrison et al., 2002) . That multiple genes restrict unlimited stem cell expansion is logical considering that unregulated expansion of self-renewing cells would lead to either hyperplasia or a frank tumor. Emerging evidence indicates that a specialized microenvironment, the stem cell niche, is one of the factors regulating normal stem cell maintenance and self-renewal. The stem cell niche controls stem cell maintenance and the crucial choice between selfrenewal and the initiation of differentiation (Spradling et al., 2001 ). Thus, stem cells appear to require paracrine signals from the cellular niche in which they reside to maintain their identity and self-renewal capacity. As a result, the number of stem cells within a particular tissue can be regulated by controlling the number or size of available niches.
The best understood examples of regulation of stem cell self-renewal by the niche are to be found in the female and male germline stem cells of the fruit fly Drosophila (Yamashita et al., 2005) . In both male and female reproductive tissues, a small number of somatic support cells provides a microenvironment that maintains the germline stem cells. Indeed, the niche cells are the source of molecules that activate signal transduction pathways in the germline stem cells specifying maintenance of stem cell fate. The stem cells physically attach to the niche and, when they divide, orient their mitotic spindles with respect to the niche, so that one daughter inherits the attachment and stays in the niche, whereas the other daughter is displaced away from the niche and activates expression of genes that launch this cell along the differentiation pathway (Chen and McKearin, 2003; Kiger et al., 2000 Kiger et al., , 2001 Tulina and Matunis, 2001; Xie and Spradling, 2000; Yamashita et al., 2003) . Additional layers of regulation may ensure that the response to the niche signal is local and that the daughter cell displaced from the niche is able to follow a developmental fate that is different from that of its sibling remaining in the niche. The mechanisms that shape the different pathways followed by the two daughter cells are not yet fully understood. However, such mechanisms may involve negative feedback loops that trigger either activation of repressors of the response to the self-renewal signal or physical isolation of the differentiating cell from the niche by enveloping guardian or escort cells (Decotto and Spradling, 2005; Kiger et al., 2000; Schulz et al., 2002) . In the Drosophila female germline, where the regulatory circuitry from the signal to the key target in the stem cell has been worked out, the main role of the signal from the niche is to block expression of genes that trigger the onset of differentiation (Chen and McKearin, 2003; Xie and Spradling, 2000) .
Recent studies suggest that cellular niches are important in preventing mammalian stem cell expansion (Calvi et al., 2003; Zhang et al., 2003) . Certain key elements of the mechanisms that specify self-renewal and prevent differentiation of stem cells in the niche may be conserved through evolution. These elements include paracrine signaling pathways, negative feedback loops that limit the response to mitogenic signals, and pathways that suppress activation of the differentiation program in stem cells. These suppression mechanisms include translational repression, as well as regulators of chromatin that repress expression of terminal differentiation genes in stem cells. A fail-safe mechanism is guaranteed by ensuring that differentiation is the default state, that is, adult stem cells are programmed to differentiate and so are lost to the pool of long-term proliferating cells unless they are located in a specific place within the niche.
Stem Cell Regulation and Cancer
Genes that program self-renewal rather than differentiation are likely to be candidate oncogenes. One of the best examples of such genes is Bmi1, a component of the Polycomb transcriptional silencing machinery that regulates transcription of target genes through epigenetic repression (Jacob et al., 1999) . Studies in the adult mouse have shown that Bmi1 is required for the maintenance of HSCs and of neural stem cells (Molofsky et al., 2003; Park et al., 2003) . The observation that active repression by Polycomb is needed for stem cell self-renewal suggests that, as in the Drosophila female germline, differentiation is the default pathway. Thus, a stem cell is only able to successfully maintain stem cell identity and self-renew when Bmi1 represses genes that promote differentiation or cell death.
The same molecular pathway that governs self-renewal in normal stem cells also seems to be usurped by cancer stem cells in leukemia and other malignancies. Emerging evidence indicates that tumors may be maintained by a subset of cancer cells with stem-cell like properties that have the capacity to self-renew. These cancer stem cells proliferate indefinitely and presumably can seed new tumors in distant sites in the body. In a mouse model of leukemia, Bmi1 is required for continued proliferation and self-renewal of leukemia stem cells. When bone marrow cells of wild-type mice are infected with a retrovirus expressing both the HoxA9 and Meis1 genesboth of which have been implicated in the development of acute leukemia-the mice die from leukemia. Importantly, however, this outcome requires functional Bmi1. Although Bmi1 mutant mice infected with the retrovirus carrying the HoxA9 and Meis1 genes exhibit leukemic blast cells in their bone marrow, the leukemia could not be transplanted to naïve secondary recipient animals (Lessard and Sauvageau, 2003) . Thus, in the absence of Bmi1, the leukemic cells failed to self-renew and eventually stopped replicating.
Characterizing the crucial role of Bmi1 in stem cell maintenance should allow identification of other key regulators in this process. Genes that turn on expression of Bmi1 and the target genes that Bmi1 represses in stem cells may also be involved in self-renewal and in cancer. For example, Sonic hedgehog (Shh) signaling, which has been implicated in the self-renewal of stem cells in both the brain and blood, can upregulate Bmi1 expression in primitive neural stem or progenitor cells (Leung et al., 2004) . Likewise, proteins such as p19
Arf , p16
Ink4a , and Tp53, whose genes are negatively regulated by Bmi1, are tumor suppressors that may be components of the fail-safe mechanisms that block inappropriate self-renewal in stem or progenitor cell lineages.
Cancer in Stem Cell and Progenitor Cell Lineages
For cancer to develop, a population of continuously proliferating (self-renewing) cells must arise. For tumors containing a subpopulation of cancer stem cells, there are at least two ways that the cancer stem cells could have arisen. In the first, oncogenic mutations may inactivate the constraints on normal stem cell expansion, resulting in cancer stem cells that originated from normal stem cells. In the second, oncogenic mutations may allow transit-amplifying cells to continue to proliferate without entering a postmitotic differentiated state, thereby creating a pool of self-renewing cells in which further mutations can accumulate. This pool ultimately may give rise to cancer stem cells that originated from a more differentiated cell.
In the first case, oncogenic mutations could arise in normal stem cells that cause defects in the mechanisms that govern stem cell dependence on the niche. For example, mutations could affect pathways that keep stem cells dependent on the niche for self-renewal. Alternatively, cancer stem cells could produce factors that recruit niche-forming cells into the tumor, resulting in an effective expansion of the niche itself (see Figure 1B ). In another model, cancer stem cells could acquire the ability to activate self-renewal pathways in response to signals that do not normally regulate this process (see Figure 1C ). There is also the possibility that cancer stem cells could activate intracellular signals normally activated by niche cells, or could express ligands usually expressed by niche-forming cells, or could constitutively activate the receptors that respond to these ligands resulting in cell-autonomous activation of selfrenewal pathways (see Figure 1D ).
In the second case, oncogenic mutations may arise that allow aberrant activation of the stem cell selfrenewal regulatory machinery in transit-amplifying cells (see Figure  1E ). This could imbue transit-amplifying progenitor cells with stemcell-like properties, thus creating a pool of cells in which further genetic events could result in progression to a fully neoplastic state. For example, certain oncogenic mutations might destroy the control sequences that activate key differentiation genes, cell-cycle inhibitors, or cell death genes that negatively regulate selfrenewal. Alternatively, oncogenic mutations could cause failure of the mechanisms that normally limit transit-amplifying cell division capacity or that initiate postmitotic differentiation (see Figure 1E ). In addition, transit-amplifying cells may escape the controls that normally limit the number of cell divisions that they undergo before they enter a postmitotic state. Because the number of transit-amplifying cells is larger than the number of stem cells, mutations that allow the transit-amplifying cells to continue to proliferate rather than to terminally differentiate may be an important step in tumor formation.
Thus, many tumors may arise through a series of mutations that disrupt normal developmental pathways, culminating in the formation of cancer stem cells that then drive tumor growth. The particular onco-genic mutations sustained by a stem cell as well as the specific interactions with the niche required for stem cell maintenance are likely to determine whether a cancer stem cell arises from a normal stem cell or from a transit-amplifying progenitor cell. Differences between normal stem cells and cancer stem cells may reveal new targets for developing therapeutics to treat cancer more effectively. For example, if there are different molecular interactions between the niche and normal and malignant stem cells, then it may be possible to find agents that specifically block self-renewal signals transmitted by the niche to cancer stem cells. Different mechanisms may regulate the programmed decline in replication potential of transit-amplifying progenitor cells and the self-renewal of normal stem cells. A clearer understanding of these pathways and how they are disrupted in cancer stem cells may lead to more effective cancer therapies.
